Fulgent Genetics (FLGT) Net Cash Flow (2015 - 2026)

Fulgent Genetics has reported Net Cash Flow for 12 years, with the latest figure at $2.8 million in Q2 2026.

• Quarterly Net Cash Flow fell 86.32% year-over-year to $2.8 million in Q2 2026, while the trailing twelve-month figure through Jun 2026 was -$61.8 million (down 370.08% YoY) and the FY2025 annual result came in at -$5.1 million, up 88.0% from the prior year.
• Net Cash Flow improved to $2.8 million in Q2 2026 per FLGT's latest filing, from -$26.8 million in the prior quarter.
• Over five years, Net Cash Flow peaked at $188.2 million in Q1 2022 and troughed at -$213.7 million in Q2 2022.
• A 5-year average of -$7.7 million and a median of $27000.0 in 2024 frame the typical range for Net Cash Flow.
• The widest YoY moves for Net Cash Flow: up 519.49% in 2025, down 2342.95% in 2025.
• Over 5 years, Net Cash Flow stood at -$89.0 million in 2022, then soared by 114.89% to $13.3 million in 2023, then plunged by 120.86% to -$2.8 million in 2024, then sank by 2342.95% to -$67.5 million in 2025, then soared by 104.17% to $2.8 million in 2026.
• According to Business Quant data, Net Cash Flow over the past three periods registered $2.8 million, -$26.8 million, and -$67.5 million for Q2 2026, Q1 2026, and Q4 2025 respectively.